Evidence map›Paper›PMID 20806340›Full record

ArticleInflammatory bowel diseases2011

Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides.

Amosy E M'Koma, Erin H Seeley, Mary K Washington, David A Schwartz, Roberta L Muldoon, Alan J Herline, Paul E Wise, Richard M Caprioli

3 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Inflammatory bowel diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03689257 completednot on this mapstarted 2017, after this paper: background citation

Prospective and Multicenter Study About the Epidemiology and the Characteristics "Omics" in Patients Recently Diagnosed of Inflammatory Bowel Disease in Spain

TypeobservationalSponsorFundación de Investigación Biomédica - Hospital Universitario de La PrincesaRan2017 to 2020Enrolled376ConditionsInflammatory Bowel Diseases
NCT03885713 phase4completednot on this mapstarted 2019, after this paper: background citation

Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches

TypeinterventionalSponsorFundación de Investigación Biomédica - Hospital Universitario de La PrincesaRan2019 to 2024Enrolled180ConditionsInflammatory Bowel Diseases, Crohn Disease, Ulcerative ColitisArmsInfliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
NCT05663671 unknown statusnot on this mapstarted 2023, after this paper: background citation

Evaluate Established Anti-DEFA5 mAbs Diagnostic Efficacy and Safety in IBD

TypeobservationalSponsorMeharry Medical CollegeRan2023 to 2025Enrolled230ConditionsInflammatory Bowel Diseases, Ulcerative Colitis, Crohn Colitis, Indeterminate ColitisArmsDiagnostic Test
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy.Nature reviews. Gastroenterology & hepatology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Amosy E M'KomaDepartment of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, Tennessee 37208-3599, USA. amkoma@mmc.edu
Erin H Seeley
Mary K Washington
David A Schwartz
Roberta L Muldoon
Alan J Herline
Paul E Wise
Richard M Caprioli
Vanderbilt University Medical Center · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Technologies and Resources CoreU54MD007593 · NIMHD · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2012 to 2018
$24.7M
ROLES OF STATS AND SRC KINASES IN GROWTH CONTROL BY IL17U54CA091408 · NCI · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2001 to 2010
$20.2M
Spatial Analysis of Molecules in Tissue using MALDI-MSR01GM058008 · NIGMS · VANDERBILT UNIVERSITY · PI CAPRIOLI, RICHARD M · 1998 to 2015
$5.8M
NCI NIH HHS 3U54CA091408-09S1NCI NIH HHS NIH/NCI-CA068485NCI NIH HHS P30 CA068485NCI NIH HHS U54 CA091408NCRR NIH HHS 1UL1 RR024975NCRR NIH HHS UL1 RR024975NIDDK NIH HHS 5P30DK58404-08NIDDK NIH HHS P30 DK058404NIGMS NIH HHS 5R01-GM58008-11NIGMS NIH HHS R01 GM058008NIMHD NIH HHS U54 MD007593
6 · The paper itself

Abstract

backgroundDifferentiating ulcerative colitis (UC) from Crohn's colitis (CC) can be difficult and may lead to inaccurate diagnoses in up to 30% of inflammatory bowel disease (IBD) patients. Much of the diagnostic uncertainty arises from the overlap of clinical and histologic features. Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) permits a histology-directed cellular protein analysis of tissues. As a pilot study, we evaluated the ability of histology-directed MALDI-MS to determine the proteomic patterns for potential differences between CC and UC specimens.

methodsMucosal and submucosal layers of CC and UC colon resection samples were analyzed after histologic assessment. To determine whether MALDI-MS would distinguish inflammation, the uninflamed (n = 21) versus inflamed submucosa (n = 22) were compared in UC and the uninflamed (n = 17) versus inflamed submucosa (n = 20) in CC. To determine whether there were proteomic differences between the colitides, the uninflamed UC submucosa (n = 21) was compared versus the uninflamed CC submucosa (n = 17), the inflamed UC submucosa (n = 22) was compared versus the inflamed CC submucosa (n = 20), and inflamed UC mucosa versus inflamed CC mucosa. Pairwise statistics comparisons of the subsets were performed.

resultsPairwise comparative analyses of the clinical groups allowed identifying subsets of features important for classification. Comparison of inflamed versus uninflamed CC submucosa showed two significant peaks: m/z 6445 (P = 0.0003) and 12692 (P = 0.003). In the case of inflamed versus uninflamed UC submucosa, several significant differentiating peaks were found, but classification was worse. Comparisons of the proteomic spectra of inflamed submucosa between UC and CC identified two discrete significant peaks: m/z 8773 (P = 0.006) and 9245 (P = 0.0009). Comparisons of the proteomic spectra of uninflamed submucosa between UC and CC identified three discrete significant peaks: m/z 2778 (P = 0.005), 9232 (P = 0.005), and 9519 (P = 0.005). No significantly different features were found between UC and CC inflamed mucosa.

conclusionsMALDI-MS was able to distinguish CC and UC specimens while profiling the colonic submucosa. Further analyses and protein identification of the differential protein peaks may aid in accurately diagnosing IBD and developing appropriate personalized therapies.

Indexed as

ProteomicsBiomarkersColitis, UlcerativeCrohn DiseaseDiscriminant AnalysisHumansMucous MembranePeptide MappingProteomeSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationBiomarkersProteome

Identifiers

PMID20806340
PMCPMC2997147
OpenAlexW2148915968

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.